BSG Pharmaceuticals was founded in 2005 in Lisbon, Portugal by Ana Beatriz Gaminha, an experienced Economist & Pharmaceutical Executive with the mission of bringing innovative medicinal products to the Portuguese market for patients in areas of unmet medical need.
Early throughout her career, Ana Beatriz continously found ways to shape her vision and the power of the mind, fueling her curiosity and stimulating her creative and innovative mindset to disrupt traditional and conventional thinking. Leveraging her sharp eyesight to spot opportunity, soon after completing her studies in Economics & Business Management at ISEG – Lisbon School of Economics & Management, she successfully secured the position of Commercial & Finance Director, first at Laboratoire Madame Campos and 2 years later as Marketing & Financial Director at Elizabeth Arden, a world reknown leader in Cosmetics, Skin Care and Fragrance Company.
Soon thereafter, Ana Beatriz transitioned to lead Roche Portugal as Country Healthcare General Manager, being part of Roche Pharmaceuticals Executive Board of Directors, where she remained for 11 years leading the strategic growth of the business and sucessfully launching differentiated products into the market.
Ana Beatriz then transitioned to Grupo Azevedos, a specialist in the Pharmaceutical Sector operating in Portugal, Angola, Mozambique and Brazil, as Executive General Manager where she was responsible for the creation of the innovative Ferrer-Azevedos Joint Venture. During this time, she successfully positioned Grupo Azevedos as one of the leading Pharmaceutical Companies based in Portugal, ultimately leading the organization to receive the prestigious Prix Galien Award in 2003. Ana Beatriz accumulated functions as Executive General Manager & Head of Hospital Business for Ferrer-Azevedos Joint Venture until 2005, when she decided to follow her entrepreneurial drive and path forward by founding the Life-Sciences Business Strategic Group – BSG Pharmaceuticals.
Since then, the company has undergone progressive transformations and reorganizations towards its envisioned future of reaching impact at scale.